Ceremonial tribute to Willy Michel at the Ypsomed General Meeting 2022

Ceremonial tribute to Willy Michel

YpsoStory

After an interruption of two years, it was with great pleasure that we were able to hold the General Meeting again physically and with a record attendance in Burgdorf. At this event, the focus was on company founder Willy Michel, who had decided to pass on the " baton" and did not stand for re-election. He had already been elected Honorary Chairman of the Ypsomed Group by the Board of Directors in May and was now bid farewell with a festive programme at the General Meeting. He will be succeeded by Gilbert Achermann, who was newly elected Chairman of the Board of Directors.

Award for our apprentices

YpsoStory

Congratulations to our apprentices: Gavin achieved second place (nationwide) in the FRAISA ToolChampions competition and came first in the regional qualifying round for German-speaking Switzerland. Stefan and Ermal both came third regionally. Gavin's podium finish at the qualifying round means that he can represent Ypsomed at the Swiss Skills in Bern – and compete for the Swiss championship.

YpsoStory

Whether it is folding envelopes, restocking supplies or taking pens apart – Max has been working at Ypsomed for more than 30 years with great pleasure and dedication. He has a cognitive disability – but that does not stop him from spreading a lot of happiness. We take a look at his activities and our cooperation with the Training and Work Centre for the Disabled (SAZ) in Burgdorf.

The success story of a life-saving hormone

YpsoStory

In July 1921, Canadian researchers Frederick Banting and his assistant Charles Best achieved a revolutionary breakthrough: they succeeded in isolating insulin from dogs’ pancreas for the first time and were also able to demonstrate its blood glucose-lowering effect - thus laying the most important foundation stone for the effective treatment of diabetes mellitus. At last there was justified hope of saving the lives of children with diabetes, who until then had only survived an average of one to two years after diagnosis without any option of therapy.